| US 7,615,648 B2 | ||
| Aminomethyl-azacycle derivatives as inhibitors of monoamine uptake | ||
| John Richard Harris, Basingstoke (United Kingdom); Barry Peter Clark, Basingstoke (United Kingdom); Peter Thaddeus Gallagher, Basingstoke (United Kingdom); and Maria Ann Whatton, Indianapolis, Ind. (US) | ||
| Assigned to Eli Lilly and Company, Indianapolis, Ind. (US) | ||
| Appl. No. 11/568,641 PCT Filed May 19, 2005, PCT No. PCT/US2005/017436 § 371(c)(1), (2), (4) Date Nov. 03, 2006, PCT Pub. No. WO2005/118531, PCT Pub. Date Dec. 15, 2005. |
||
| Claims priority of provisional application 60/576059, filed on Jun. 01, 2004. | ||
| Prior Publication US 2008/0004330 A1, Jan. 03, 2008 | ||
| Int. Cl. C07D 207/00 (2006.01); A01N 43/36 (2006.01) | ||
| U.S. Cl. 548—566 [514/408] | 7 Claims |
1. A compound of formula (I)
 A is
 R1 is ethyl, propyl, isopropyl, isobutyl, 2,2-dimethylpropyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, tetrahydrofuran-3-yl,
tetrahydropyran-4-yl or 8-oxabicyclo[3.2.1]oct-6endo-yl;
R7 is independently at each occurrence selected from H and C1-C4alkyl;
y is 1, 2 or 3;
Ar1 is
 R2 is H, halogen, C1-C4alkyl (optionally substituted with from 1 to 3 halogen atoms), —O-(C1-C4alkyl) (optionally substituted with from 1 to 3 halogen atoms) or phenyl;
R3 is H, halogen or C1-C4alkyl (optionally substituted with from 1 to 3 halogen atoms);
R4 is H, halogen or C1-C4alkyl (optionally substituted with from 1 to 3 halogen atoms);
R5 is H, halogen or C1-C4alkyl (optionally substituted with from 1 to 3 halogen atoms); and
R6 is H;
or a pharmaceutically acceptable salt thereof.
|